Vivoryon Therapeutics NV

NEW
STU:05Y (Germany)  
€ 8.13 (0%) Nov 8
At Loss
P/B:
4.31
Market Cap:
€ 57.48M ($ 61.63M)
Enterprise V:
€ 42.14M ($ 45.19M)
Volume:
-
Avg Vol (2M):
-
Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Vivoryon Therapeutics NV ( STU:05Y ) from 2017 to Nov 10 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Vivoryon Therapeutics NV stock (STU:05Y) PE ratio as of Nov 10 2024 is 0. More Details

Vivoryon Therapeutics NV (STU:05Y) PE Ratio (TTM) Chart

To

Vivoryon Therapeutics NV (STU:05Y) PE Ratio (TTM) Historical Data

Total 1249
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Vivoryon Therapeutics NV PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-11-10 At Loss 2024-09-06 At Loss
2024-11-08 At Loss 2024-09-05 At Loss
2024-11-07 At Loss 2024-09-04 At Loss
2024-11-06 At Loss 2024-09-03 At Loss
2024-11-05 At Loss 2024-09-02 At Loss
2024-11-04 At Loss 2024-08-30 At Loss
2024-11-01 At Loss 2024-08-29 At Loss
2024-10-30 At Loss 2024-08-28 At Loss
2024-10-29 At Loss 2024-08-27 At Loss
2024-10-28 At Loss 2024-08-26 At Loss
2024-10-25 At Loss 2024-08-23 At Loss
2024-10-24 At Loss 2024-08-22 At Loss
2024-10-23 At Loss 2024-08-21 At Loss
2024-10-22 At Loss 2024-08-20 At Loss
2024-10-21 At Loss 2024-08-19 At Loss
2024-10-18 At Loss 2024-08-16 At Loss
2024-10-17 At Loss 2024-08-15 At Loss
2024-10-16 At Loss 2024-08-14 At Loss
2024-10-15 At Loss 2024-08-13 At Loss
2024-10-14 At Loss 2024-08-12 At Loss
2024-10-11 At Loss 2024-08-09 At Loss
2024-10-10 At Loss 2024-08-08 At Loss
2024-10-09 At Loss 2024-08-07 At Loss
2024-10-08 At Loss 2024-08-06 At Loss
2024-10-07 At Loss 2024-08-05 At Loss
2024-10-04 At Loss 2024-08-02 At Loss
2024-10-03 At Loss 2024-08-01 At Loss
2024-10-02 At Loss 2024-07-31 At Loss
2024-10-01 At Loss 2024-07-30 At Loss
2024-09-30 At Loss 2024-07-29 At Loss
2024-09-27 At Loss 2024-07-26 At Loss
2024-09-26 At Loss 2024-07-25 At Loss
2024-09-25 At Loss 2024-07-24 At Loss
2024-09-24 At Loss 2024-07-23 At Loss
2024-09-23 At Loss 2024-07-22 At Loss
2024-09-20 At Loss 2024-07-19 At Loss
2024-09-19 At Loss 2024-07-18 At Loss
2024-09-18 At Loss 2024-07-17 At Loss
2024-09-17 At Loss 2024-07-16 At Loss
2024-09-16 At Loss 2024-07-15 At Loss
2024-09-13 At Loss 2024-07-12 At Loss
2024-09-12 At Loss 2024-07-11 At Loss
2024-09-11 At Loss 2024-07-10 At Loss
2024-09-10 At Loss 2024-07-09 At Loss
2024-09-09 At Loss 2024-07-08 At Loss

Vivoryon Therapeutics NV (STU:05Y) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products include PQ912 and PQ1565. Geographically, the majority is from Greater China.